Published in Neurotox Res on November 13, 2014
Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders. Psychopharmacology (Berl) (2016) 0.77
Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson's disease: mitochondrial DNA integrity. Arch Med Sci (2017) 0.75
Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Caffeine Augments The Instruction of Anti-Inflammatory Macrophages by The Conditioned Medium of Mesenchymal Stem Cells. Cell J (2017) 0.75
Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev (1999) 6.26
Nomenclature and classification of purinoceptors. Pharmacol Rev (1994) 5.32
Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol (2005) 5.13
Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol (2006) 2.60
The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci (2006) 2.44
Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol (2001) 2.31
Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci (2006) 2.29
Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci (1997) 2.23
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther (2006) 2.03
Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci (1994) 1.87
3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) (2006) 1.66
Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann N Y Acad Sci (2010) 1.54
Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol (2009) 1.42
Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci (2011) 1.35
Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav (2007) 1.27
Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. J Neurosci Res (2006) 1.26
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol (2008) 1.24
Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. J Med Chem (1988) 1.23
Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem (1996) 1.14
N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology (2005) 1.14
Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett (1996) 1.07
Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. J Neurochem (2007) 1.05
An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology (1998) 1.05
D1 and D2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats. Pharmacol Biochem Behav (1994) 1.04
Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology (2006) 1.03
Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci (2000) 0.99
A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. Br J Pharmacol (2001) 0.98
Combination of adenosine A1 and A2A receptor blocking agents induces caffeine-like locomotor stimulation in mice. Eur Neuropsychopharmacol (2005) 0.94
Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol Biochem Behav (1993) 0.93
The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol (1988) 0.91
Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol (1997) 0.91
Decreased behavioral activation following caffeine, amphetamine and darkness in A3 adenosine receptor knock-out mice. Physiol Behav (2008) 0.90
Differential effects of adenosine receptor subtypes on release and reuptake of hippocampal serotonin. Eur J Neurosci (1999) 0.87
Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX. Psychopharmacology (Berl) (1991) 0.87
Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents. Neurosci Lett (1996) 0.86
Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum. Neurotox Res (2009) 0.86
What knock-out animals tell us about the effects of caffeine. J Alzheimers Dis (2010) 0.86
Chronic coffee and caffeine ingestion effects on the cognitive function and antioxidant system of rat brains. Pharmacol Biochem Behav (2011) 0.86
Role of nicotinic acetylcholine receptors in regulating dopamine neuron activity. Neuroscience (2014) 0.84
Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists. Neurology (2003) 0.83
Caffeine potentiates methamphetamine-induced toxicity both in vitro and in vivo. Neurosci Lett (2011) 0.83
The role of adenosine receptor agonist and antagonist on Hippocampal MDMA detrimental effects; a structural and behavioral study. Metab Brain Dis (2012) 0.83
The effect of adenosine A(2A) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2. Neurotox Res (2012) 0.82
Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in rats. Br J Pharmacol (2010) 0.81
Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. Neurotox Res (2009) 0.81
Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love"). Neuropharmacology (2005) 0.81
Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Res (1998) 0.81
Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum. Brain Res (2009) 0.81
Methylxanthine effects on caudate dopamine release as measured by in vivo electrochemistry. Life Sci (1989) 0.81
In vivo labelling of the adenosine A2A receptor in mouse brain using the selective antagonist [3H]SCH 58261. Eur J Neurosci (2001) 0.80
Influence of chronic caffeine on MDMA-induced behavioral and neuroinflammatory response in mice. Psychopharmacology (Berl) (2012) 0.80
DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). Psychopharmacology (Berl) (2003) 0.80
Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorg Med Chem (2003) 0.80
A role for adenosine A(1) receptor blockade in the ability of caffeine to promote MDMA "Ecstasy"-induced striatal dopamine release. Eur J Pharmacol (2010) 0.80
Caffeine and regional brain monoamine utilization in mice. Life Sci (1989) 0.79
Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum. Pharmacol Rep (2008) 0.79
Adenosine receptors--the role in modulation of dopamine and glutamate release in the rat striatum. Pol J Pharmacol (1998) 0.79
Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease. Neurotox Res (2013) 0.79
Risk of caffeine toxicity associated with the use of 'legal highs' (novel psychoactive substances). Eur J Clin Pharmacol (2011) 0.78
Regional differences in the ability of caffeine to affect haloperidol-induced striatal c-fos mRNA expression in the rat. Neuropharmacology (1998) 0.77
The interactions of caffeine with monoamine oxidase. Life Sci (2013) 0.77
MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex. Psychopharmacology (Berl) (2014) 0.76
In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.76
Influence of CGS 15943 A (a nonxanthine adenosine antagonist) on the protection offered by a variety of antiepileptic drugs against maximal electroshock-induced seizures in mice. J Neural Transm Gen Sect (1991) 0.76
Pharmacodynamic interactions between MDMA and concomitants in MDMA tablets on extracellular dopamine and serotonin in the rat brain. Eur J Pharmacol (2011) 0.76
The effect of caffeine on MDMA-induced hydroxyl radical production in the mouse striatum. Pharmacol Rep (2014) 0.75
The effect of p-chloroamphetamine and p-chlorophenylalanine on the level of thyrotropin-releasing hormone and its receptors in some brain structures and lumbar spinal cord of the rat. Neuropeptides (1992) 0.84
Evidence that conditioned stress enhances outflow of dopamine in rat prefrontal cortex: a search for the influence of diazepam and 5-HT1A agonists. Synapse (1996) 0.83
Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent. Neuropharmacology (2007) 0.83
The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids (2009) 0.82
Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex. Eur J Pharmacol (1996) 0.82
Prenatal lipopolysaccharide treatment enhances MK-801-induced psychotomimetic effects in rats. Pharmacol Biochem Behav (2011) 0.82
Melatonin increases serotonin N-acetyltransferase activity and decreases dopamine synthesis in light-exposed chick retina: in vivo evidence supporting melatonin-dopamine interaction in retina. J Neurochem (1992) 0.81
Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats. Neuroscience (2000) 0.80
The role of dopamine in regulation of thyrotropin-releasing hormone in the striatum and nucleus accumbens of the rat. Neuropeptides (1991) 0.80
MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res (1993) 0.79
Intraperitoneal zinc administration increases extracellular zinc in the rat prefrontal cortex. J Physiol Pharmacol (2008) 0.79
The role of striatal metabotropic glutamate receptors in Parkinson's disease. Amino Acids (2002) 0.78
Involvement of 5-HT1A receptors in the antidepressant-like activity of gepirone in the forced swimming test in rats. Neuropharmacology (1991) 0.78
Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity. Pol J Pharmacol (1994) 0.77
MK-801-induced symptoms of sensitization. The lack of correlation with the extracellular concentration of dopamine in the rat prefrontal cortex. Brain Res (1993) 0.76
EMD 57445, the selective sigma receptor ligand, has no effect on the 5-hydroxytryptamine system. Pol J Pharmacol (1998) 0.75
Concomitant administration of MK-801 and desipramine enhances extracellular concentration of dopamine in the rat prefrontal cortex. Neuroreport (1993) 0.75
Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.75
Serotonin, dopamine, noradrenaline and their metabolites: levels in the brain of the house cricket (Acheta domesticus L.) during a 24-hour period and after administration of quipazine--a 5-HT2 receptor agonist. Comp Biochem Physiol C (1991) 0.75
Effect of EMD 57445, the selective sigma receptor ligand, on the turnover and release of dopamine. Pol J Pharmacol (1998) 0.75
The effect of fenfluramine on the thyrotropin-releasing hormone (TRH) content in the rat brain structures and lumbar spinal cord. Neuropeptides (1990) 0.75